新型冠状病毒病 2019（COVID-19）：临床更新。
Coronavirus disease 2019 (COVID-19): a clinical update.
机构信息
National Research Center for Translational Medicine, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China.
Department of Respiratory and Critical Care Medicine, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China.
出版信息
Front Med. 2020 Apr;14(2):126-135. doi: 10.1007/s11684-020-0767-8. Epub 2020 Apr 2.
Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has posed a significant threat to global health. It caused a total of 80 868 confirmed cases and 3101 deaths in Chinese mainland until March 8, 2020. This novel virus spread mainly through respiratory droplets and close contact. As disease progressed, a series of complications tend to develop, especially in critically ill patients. Pathological findings showed representative features of acute respiratory distress syndrome and involvement of multiple organs. Apart from supportive care, no specific treatment has been established for COVID-19. The efficacy of some promising antivirals, convalescent plasma transfusion, and tocilizumab needs to be investigated by ongoing clinical trials.
截至 2020 年 3 月 8 日，中国内地累计报告新冠肺炎确诊病例 80868 例，死亡 3101 例。由严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）引起的 2019 年冠状病毒病（COVID-19）对全球健康构成了重大威胁。这种新型病毒主要通过呼吸道飞沫和密切接触传播。随着疾病的进展，一系列并发症往往会发展，特别是在重症患者中。病理发现显示出急性呼吸窘迫综合征的典型特征，并涉及多个器官。除了支持性护理外，目前还没有针对 COVID-19 的特定治疗方法。一些有前途的抗病毒药物、恢复期血浆输注和托珠单抗的疗效需要通过正在进行的临床试验来研究。
Zotero 插件